SIERRA Trial Delivers Initial Data for Older Patients With AML
Rajneesh Nath, MD, discusses the early results of the phase III SIERRA trial investigating the efficacy of Iomab-B and protocol-specified allogeneic hematopoietic stem cell transplant versus the standard of care in older patients with active, relapsed or refractory acute myeloid leukemia.
Rajneesh Nath, MD, a medical oncologist at the Banner MD Anderson Cancer Center, discusses the early results of the phase III SIERRA trial (NCT02665065) investigating the efficacy of Iomab-B and protocol-specified allogeneic hematopoietic stem cell transplant (HCT) versus the standard of care in older patients with active, relapsed or refractory acute myeloid leukemia (AML).
Nath says that the safety of the Iomab-B, a reduced intensity conditioning regimen, and HCT combination was 1 of the most important parts of this multicenter trial. The study investigators looked at data after half of the patients on the trial were randomized. Thus far, they have reported that about 80% of the patients in the Iomab-B arm were unable to undergo transplant. They also had fully engrafted neutrophils and platelets.
In the conventional arm, about 20% of patients were able to undergo the standard-of-care transplant. However, this study allowed patients who did not go into remission to crossover from convention chemotherapy to the HCT and Iomab-B regimen, which was about 80% of patients, according to Nath.
